Drugs / TAS-119
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02448589 | Sep 2014 → Aug 2019 | cancer | Taiho Oncology, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02134067 | Aug 2014 → Jul 2018 | cancer | Taiho Oncology, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS-119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02134067 ↗ |
| Action | Inhibit | “TAS-119 selectively inhibits the kinase inhibitor Aurora A.” NCT02134067 ↗1“Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL3692206 ↗ |
| Modality | Small molecule | — CHEMBL3692206 ↗ |
| Route | Oral | “TAS-119 tablets, oral” NCT02134067 ↗ |
| Target | AURKA | “Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL3692206 ↗ |